| abstract |
The present invention relates to 2- (3- {6- [2- (2,4-dichloro-phenyl) -ethylamino] -2-methoxy-pyrimidin-4-yl} -phenyl) -2- A pharmaceutical composition comprising a dihydrogen phosphate of methyl-propionic acid, a pharmaceutically effective amount of a compound of formula III and a pharmaceutically acceptable carrier, and an allergic disease (eg, by administering to the patient a pharmaceutically effective amount of a compound of formula III) For example, allergic rhinitis, allergic conjunctivitis, atopic dermatitis, bronchial asthma and food allergy), systemic mastocytosis, disorders with systemic mast cell activation, anaphylactic shock, bronchial contraction, bronchitis, urticaria, eczema, pruritus Disease (eg, cataracts, retinal detachment, inflammation, infection, and secondary disease) that occurs as a result of a disease (eg, atopic dermatitis and urticaria), behavior with pruritus (eg, scratching and tapping) Sleep disorder ), Methods of treating patients suffering from PGD2-mediated disorders, including but not limited to inflammation, chronic obstructive pulmonary disease, ischemic reperfusion injury, cerebrovascular accident, chronic rheumatoid arthritis, pleurisy, ulcerative colitis, etc. will be:n n n Formula III |